Anonymous
Guest
Anonymous
Guest
Novartis blatantly asked their reps to segment the hypertensive market. Diovan was to be sold for the uncomplicated hypertensive patient, post mi, and for heart failure. Tekturna products were to be promoted for the diabetic hypertensive patient. Add Tekturna to an ACE or an ARB in a diabetic patient. Sure there is a study showing that when Tekturna is added to Ramipril it provides an additional 40% efficacy for the diabetic hypertensive patient. However, if you looked at the Tekturna pi under indications there never was an indication for diabetic hypertensives. In fact the word diabetic was not even mentioned anywhere in the indications section. I ask who is the first rep to sue Novartis for promoting off label?